Takeda’s plasma manufacturing facility approved by FDA

By Maggie Lynch

- Last updated on GMT

(Image: Getty/ Iido Frazao)
(Image: Getty/ Iido Frazao)

Related tags Fda Manufacturing Takeda Shire

US FDA approves Takeda’s acquired plasma manufacturing facility in Georgia, US, for the production of flexbumin 25% solution.

Takeda’s acquired plasma manufacturing plant located near Covington, Georgia, was approved by the US Food and Drug Administration (FDA) for the production of flexbumin (albumin (human)) 25% solution.

The approved facility will provide additional capacity to meet increasing global demand for plasma-derived therapies, according to Takeda. Additional scale up of production will occur at the plant over the next few years.

Takeda acquired Shire in December 2018​, after which Takeda created a business unit to meet the global demand for plasma-derived products. “Our strategic focus and increased investment in plasma innovation will enable us to expand,”​ a spokesperson for Takeda told us.

Before being acquired by Takeda, Shire filed an FDA submission​ to manufacture the plasma-volume replacement therapy, flexbumin, at its $1.2bn (€1bn) plant in October 2018.

In June 2018, the FDA approved the Georgia facility for the production of gammagard liquid (immune globulin infusion (human)) 10% solution. Shire sought FDA approval​ to manufacture at the facility in January 2018.

The Georgia facility currently employs approximately 1,000 full-time and contract employees, it will look to hire further staff to fill additional roles at the plant.

Related news

Show more

Related product

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers